Skip to main content
. 2021 Feb 9;13(4):713. doi: 10.3390/cancers13040713

Figure 1.

Figure 1

The extracellular matrix (ECM) components that participate in triple-negative breast carcinoma (TNBC) progression include among others major epithelial-to-mesenchymal transition (EMT) biomarkers (E-cadherin, N-cadherin, vimentin, TGF-β etc.), matrix enzymes (matrix metalloproteinases (MMPs), heparanase (HPSE), LOX, HASes, etc.), proteoglycans/glycosaminoglycans (syndecans, CD44, HA etc.), miRNAs (let-7, miR-7, miR-10b, miR-27a, miR-145, miR-200, miR-203 etc.) and estrogen receptors (ERα/β), that affect the activation of signaling pathways critical for the control of TNBC cell properties (PI3K/AKT, ERK1/2, JNK, Src, JAK2/STAT5, WNT, Notch etc.).